PhenomeX has been granted a patent for a polymerase enzyme from 9° N with enhanced ability to incorporate reversible terminating nucleotides. The enzyme contains specific mutations and minimal 3′-5′ exonuclease activity. This innovation opens new possibilities in genetic research and diagnostics. GlobalData’s report on PhenomeX gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights PhenomeX Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on PhenomeX, was a key innovation area identified from patents. PhenomeX's grant share as of February 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Polymerase enzyme with improved nucleotide incorporation and no exonuclease activity

Source: United States Patent and Trademark Office (USPTO). Credit: PhenomeX Inc

A recently granted patent (Publication Number: US11866741B2) discloses a novel polymerase enzyme with specific mutations that result in little to no 3'-5' exonuclease activity. The enzyme, sharing at least 95% amino acid sequence identity to SEQ ID NO:1, includes mutations L408S, Y409G, and P410S. Additionally, the polymerase may belong to the genera of Pyrococcus and contain further mutations like D141A, E143A, and A485L, enhancing its functionality for nucleotide incorporation.

Moreover, the patent covers methods for utilizing this polymerase in DNA sequencing, labeling, primer extension, and nucleic acid amplification. By incorporating nucleotides modified at the 3' sugar hydroxyl with larger substituents, the polymerase demonstrates increased efficiency in primer extension reactions. The patent also includes the nucleic acid molecule encoding the polymerase, an expression vector, and a comprehensive kit for practical applications, highlighting the potential for advancements in genetic research and biotechnology with this innovative enzyme.

To know more about GlobalData’s detailed insights on PhenomeX, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies